UNASSIGNED: Radiotherapy is a major treatment modality for @entity213 ( @entity213 ). Up to 50% of @entity1 with locally advanced disease relapse after radical treatment and there is therefore a need to develop predictive bomarkers for clinical use that allow the selection of @entity1 who are likely to respond. MicroRNA (miRNA) expression profiling of a panel of @entity213 with and without recurrent disease after surgery and radiotherapy detected miR-196a as one of the highest upregulated miRNAs in the poor prognostic group. To further study the role of miR-196a, its expression was determined in eight @entity135 cell lines. Overexpression of miR-196a in @entity213 cells, with low endogenous miR-196a expression, significantly increased cell proliferation, @entity4222 and invasion, and induced epithelial to mesenchymal transition. Conversely, miR-196a knockdown in cells with high endogenous expression levels significantly reduced oncogenic behaviour. Importantly, overexpression of miR-196a increased radioresistance of cells as measured by gamma @entity6714 staining and @entity98 survival assay. @entity216 ( @entity216 ), a known target of miR-196a, was found to be directly modulated by miR-196a as measured by luciferase assay and confirmed by Western blot analysis. @entity216 knockdown in @entity213 exhibited similar phenotypic effects to miR-196a overexpression, suggesting the oncogenic effect of miR-196a may at least be partly regulated through suppression of @entity216 . In conclusion, this study identifies miR-196a as a potential important biomarker of prognosis and response of @entity213 to radiotherapy. Furthermore, our data suggest that miR-196a and/or its target gene @entity216 could represent important therapeutic targets in @entity213 .

MicroRNA-196a promotes an oncogenic effect in XXXX cells by suppressing @entity216 and enhancing radioresistance.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity4222 :: ('MESH:D014085', 'Disease') :: ['migration'] @entity216 :: ('301', 'Gene') :: ['Annexin A1', 'ANXA1'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity6714 :: ('3014', 'Gene') :: ['H2AX'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC tumours', 'head and neck squamous cell carcinoma', 'HNSCC']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']
